Paper
0
Efficacy of Selpercatinib in RET-Altered Thyroid Cancers
Authors
Lori Wirth,Eric Sherman
Bruce Robinson,Benjamin Solomon,Hyunseok Kang,Jochen Lorch,Francis Worden,Marcia Brose,Jyoti Patel,Sophie Leboulleux,Yann Godbert,Fabrice Barlési,John Morris,Taofeek Owonikoko,Daniel Tan,Oliver Gautschi,Jared Weiss,Christelle Fouchardière,Mark Burkard,Janessa Laskin,Matthew Taylor,Matthias Kroiß,Jacques Médioni,Jonathan Goldman,Todd Bauer,Benjamin Levy,Viola Zhu,Nehal Lakhani,Víctor Moreno,Kevin Ebata,Michele Nguyen,Dana Heirich,Edward Zhu,Xin Huang,Luxi Yang,Jennifer Kherani,S. Rothenberg,Alexander Drilon,Vivek Subbiah,Manisha Shah
+38 authors
,Maria CabanillasPublished
Aug 26, 2020
Show more
Save
Tip0
TipSave
Abstract
RET mutations occur in 70% of medullary thyroid cancers, and RET fusions occur rarely in other thyroid cancers. In patients with RET-altered thyroid cancers, the efficacy and safety of selective RET inhibition are unknown.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.